{"abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Cardiovascular and Renal Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Cardiovascular and Renal Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the August 27, 2028, expiration date.","action":"Notice; renewal of Federal advisory committee.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2026/08/20/2026-16999.html","cfr_references":[],"citation":"91 FR 53882","comment_url":null,"comments_close_on":null,"correction_of":null,"corrections":[],"dates":"Authority for the Cardiovascular and Renal Drugs Advisory Committee will expire on August 27, 2026, unless the Commissioner formally determines that renewal is in the public interest.","disposition_notes":null,"docket_ids":["Docket No. FDA-2026-N-0008"],"dockets":[{"supporting_documents":[],"agency_name":"FDA","documents":[{"comment_count":0,"comment_start_date":"2026-08-20","updated_at":"2026-08-20T10:57:27.330-04:00","comment_url":"https://www.regulations.gov/commenton/FDA-2026-N-0008-0011","allow_late_comments":false,"id":"FDA-2026-N-0008-0011","comment_end_date":null,"regulations_dot_gov_open_for_comment":false}],"supporting_documents_count":0,"id":"FDA-2026-N-0008","title":"Advisory Committee"}],"document_number":"2026-16999","effective_on":null,"end_page":53884,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2026/08/20/2026-16999.xml","html_url":"https://www.federalregister.gov/documents/2026/08/20/2026-16999/advisory-committee-cardiovascular-and-renal-drugs-advisory-committee-renewal","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2026-16999?publication_date=2026-08-20","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2026-08-20/2026-16999/mods.xml","not_received_for_publication":null,"page_length":3,"page_views":{"count":229,"last_updated":"2026-10-25 10:15:05 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-20/pdf/2026-16999.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16999.pdf?1787143523","publication_date":"2026-08-20","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2026/08/20/2026-16999.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_count":0,"agency_id":"FDA","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2026-N-0008","supporting_documents_count":0,"docket_id":"FDA-2026-N-0008","document_id":"FDA-2026-N-0008-0011","regulation_id_number":null,"title":"Advisory Committee","checked_regulationsdotgov_at":"2026-08-21T17:55:06Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":53882,"subtype":null,"title":"Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal","toc_doc":"Cardiovascular and Renal Drugs Advisory Committee","toc_subject":"Charter Amendments, Establishments, Renewals and Terminations","topics":[],"type":"Notice","volume":91}